OP \$1400.00 533473

PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Natural Pharma Canada, ULC	01/05/2010
Natural Pharmaceuticals, Inc.	01/05/2010

RECEIVING PARTY DATA

Name:	Phyton, Inc.		
Street Address:	318 McCullough Avenue		
City:	San Antonio		
State/Country:	TEXAS		
Postal Code:	78215		

PROPERTY NUMBERS Total: 35

Property Type	Number
Patent Number:	5334732
Patent Number:	5336684
Patent Number:	5356928
Patent Number:	5364947
Patent Number:	5412116
Patent Number:	5449790
Patent Number:	5629433
Patent Number:	5679807
Patent Number:	5792877
Patent Number:	5808113
Patent Number:	5892063
Patent Number:	6956123
Patent Number:	7176325
Patent Number:	7220872
	PATENT

REEL: 023741 FRAME: 0771

501059543

Application Number:	07909080
Application Number:	07973076
Application Number:	08323275
Application Number:	08331682
Application Number:	08401711
Application Number:	08431906
Application Number:	08617391
Application Number:	10522696
Application Number:	10549490
Application Number:	11173477
Application Number:	11196950
Application Number:	11764362
Application Number:	60370252
Application Number:	60370583
Application Number:	60401191
Application Number:	60437237
Application Number:	60437434
Application Number:	60444847
Application Number:	60455377
Application Number:	60456478
Application Number:	61031467

CORRESPONDENCE DATA

Fax Number: (512)536-4598

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 5124745201

Email: rortiz@fulbright.com

Correspondent Name: Michael R. Krawzsenek

Address Line 1: 600 Congress Avenue

Address Line 2: Suite 2400

Address Line 4: Austin, TEXAS 78701

ATTORNEY DOCKET NUMBER: DFBP:001/ 10507643

NAME OF SUBMITTER: Michael R. Krawzsenek

Total Attachments: 3

source=DFBP001 - ASSIGNMENT FROM NATURAL PHARMA CANADA-NATURAL PHARMA TO PHYTON#page1.tif source=DFBP001 - ASSIGNMENT FROM NATURAL PHARMA CANADA-NATURAL PHARMA TO PHYTON#page2.tif source=DFBP001 - ASSIGNMENT FROM NATURAL PHARMA CANADA-NATURAL PHARMA TO PHYTON#page3.tif

PATENT

REEL: 023741 FRAME: 0772

PATENT ASSIGNMENT

WHEREAS, Natural Pharma Canada, ULC, a Nova Scotia unlimited liability corporation and Natural Pharmaceuticals, Inc., a Delaware corporation (hereinafter collectively, the "ASSIGNOR"), is(are) the owner(s) of the patents and patent applications identified on Exhibit A (collectively, the "Patents");

AND WHEREAS, Phyton, Inc., a Delaware corporation (hereinafter the "ASSIGNEE"), is desirous of acquiring all right, title and interest in and to the Patents;

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, ASSIGNOR does hereby:

IRREVOCABLY SELL, ASSIGN, AND TRANSFER to the ASSIGNEE the entire right, title and interest for the United States and all foreign countries in and to any and all improvements which are disclosed in the Patents, including but not limited to the right to sue for injunctions and/or damages for any past, ongoing, and/or future infringement;

AUTHORIZE AND REQUEST the issuing authority to issue any and all United States and foreign patents granted on such improvements to the ASSIGNEE;

WARRANT AND COVENANT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned, and that the full right to convey the same as herein expressed is possessed by the undersigned; and

COVENANT, when requested and at the expense of the ASSIGNEE, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all such improvements; execute all rightful oaths, declarations, assignments, powers of attorney and other papers; communicate to the ASSIGNEE all facts known to the undersigned relating to such improvements and the history thereof; and generally do everything possible which the Assignee shall consider desirable for vesting title to such improvements in the Assignee, and for securing, maintaining and enforcing proper patent protection for such improvements.

70606547.2

and extend to the successors, assigns and nominees of the ASSIGNEE.
NATURAL PHARMA CANADA, ULC
Signature: January 5, 2010 Name: Roland P. Franke
Title: CEO
STATE OF
COUNTY OF
BEFORE ME, the undersigned authority, on this, day of, 2010 personally appeared, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.
Notary or Consular Officer
[SEAL]
NATURAL PHARMACEUTICALS, INC.
Signature: January 5, 2010 Name: Roland R. Franke Title: CFO
STATE OF COUNTY OF
BEFORE ME, the undersigned authority, on this day of, 2009 personally appeared, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.
Notary or Consular Officer [SEAL]

TO BE BINDING on the heirs, assigns, representatives and successors of the undersigned

-2-

Exhibit A

All U.S. and non-U.S. patents and applications owned by the ASSIGNOR as of the date first written above, including, but not limited to, the patents and applications (and any related continuing, continuation, continuation-in-part, divisional, renewal, reissue, substitute patents and applications thereof) identified in the following table:

U.S. Patents	U.S. Applications	Non-U.S. Patents/App	plications	
5,334,732	07/909,080	Argentina	Europe	PCT/International
5,336,684	07/973,076	P04-01-00896	EP 696279	PCT/US1993/10580
5,356,928	08/323,275		EP 0755387	PCT/US1994/04519
5,364,947	08/331,682	Australia	EP 0668862	PCT/US1994/10525
5,412,116	08/401,711	AU 1994067735	EP 95915472.5	PCT/US1995/03975
5,449,790	08/431,906	AU 1994078367	EP 95915543.3	PCT/US1995/04172
5,629,433	08/617,391	AU 1995022342	EP 96907021.8	PCT/US1995/008849
5,679,807	10/522,696	AU 1995022392	EP 96909628.8	PCT/US1996/001322
5,792,877	10/549,490	AU 1995031278	EP 03728345.4	PCT/US1996/003242
5,808,113	11/173,477	AU 1996050210	EP 1497276	PCT/US2004/008055
5,892,063	11/196,950	AU 1996053057	EP 03767262.3	PCT/US2003/010556
6,956,123	11/764,362	AU 2004221834	EP 03815018.1	PCT/US2003/010557
7,176,325	60/370,252	AU 2003234689	EP 04707837.3	PCT/US2003/024666
7,220,872	60/370,583	AU 2003226287	EP 04757522.0	PCT/US2003/041824
	60/401,191	AU 2003256861		PCT/US2003/041774
	60/437,237	AU 2003303565	Germany	PCT/US2004/003259
	60/437,434	AU 2003300164	DE 69402311	
	60/444,847	AU 19940055476	DE 69511257	
	60/455,377	AU 685119	DE 69332223	
	60/456,478	AU 694627	DE 60323079	
	61/031,467			
		Canada	Japan	
		CA 2161138	JP 94-524451	
		CA 2187337	JP 3759602	
		CA 2148943	JP 696279	
		CA 2187191	JP 3878204	
		CA 2211799	JP 08-523705	:
		CA 2214993	JP 08-527756	
		CA 2519474	JP 2006-507246	
		CA 2495476	JP 2004-526071	
		CA 2512095	JP 2007-76064	
		CA 2512170		
			Spain	
		China	ES 2181706	
		CN 200480013498.X	ES 2312800	
		CN 03823660.5		
			Taiwan	
			93107087	

70606547.2 A-1

RECORDED: 01/07/2010

PATENT REEL: 023741 FRAME: 0775